Uncategorized
Bill Ackman Sends UnitedHealth Stock Lower With Deleted Tweet: Here’s What He Said
Bill Ackman shared choice comments on UnitedHealth Group on his social media account before deleting his posts. Here’s a look at what the hedge funder said. read more
Bitcoin Struggling But ‘Perfect Storm’ Will Take It To $500,000, Ethereum To $20,000, Trader Predicts
Crypto analyst Michaёl van de Poppe urges investors to hold their crypto assets, emphasizing that Bitcoin (CRYPTO: BTC) is fairly valued while altcoins remain heavily undervalued. read more
What 4 Analyst Ratings Have To Say About CVRx
Latest Ratings for CVRX Date Firm Action From To Jul 2021 William Blair Initiates Coverage On Outperform Jul 2021 Canaccord Genuity Initiates Coverage On Buy Jul 2021 JP Morgan Initiates Coverage On Overweight View More Analyst Ratings for CVRX View the Latest Analyst Ratings read more
Breaking Down Intapp: 9 Analysts Share Their Views
Latest Ratings for INTA Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Jan 2022 Piper Sandler Maintains Overweight Nov 2021 Piper Sandler Maintains Overweight View More Analyst Ratings for INTA View the Latest Analyst Ratings read more
Assessing Pentair: Insights From 10 Financial Analysts
Latest Ratings for PNR Date Firm Action From To Mar 2022 Mizuho Upgrades Underperform Neutral Feb 2022 Morgan Stanley Maintains Underweight Jan 2022 Morgan Stanley Maintains Underweight View More Analyst Ratings for PNR View the Latest Analyst Ratings read more
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024. Latest Ratings for LLY Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Mizuho Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for…
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook. Latest Ratings for MRK Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Jan 2022 JP Morgan Maintains Overweight Dec 2021 Daiwa Capital Initiates Coverage On Neutral View More Analyst Ratings…